FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308984611> ?p ?o ?g. }

• W4308984611 endingPage "1057" @default.
• W4308984611 startingPage "1057" @default.
• W4308984611 abstract "<h3>Purpose/Objective(s)</h3> The role of SBRT in the treatment of HCC is not well established. The hypothesis of this study was that overall survival (OS) would improve with SBRT followed by sorafenib (SBRT/S) vs. sorafenib alone (S), in patients with advanced HCC. <h3>Materials/Methods</h3> Eligible patients had new or recurrent HCC, unsuitable for resection, transplant, ablation or TACE, with Zubrod performance status (PS) 0-2, Child-Pugh A, intermediate (B) or advanced (C) Barcelona Clinic Liver Cancer Stage (BCLC), ≤ 5 HCCs, sum of hepatic HCCs ≤ 20 cm, and sum of extrahepatic metastases ≤ 3 cm. Patients were randomized 1:1 to S 400 mg BID vs. SBRT (27.5-50Gy in 5 fractions, with dose individualized based on mean liver dose and other dose constraints) followed by S 200 mg BID then increased to 400 mg BID after 28 days if appropriate. Primary endpoint was OS. Reported secondary endpoints were progression-free survival (PFS), time to progression (TTP), and adverse events (AEs - CTCAEv4). Planned sample size was 292 patients (238 OS events, HR=0.72, 80% power, 1-sided alpha=0.05). Accrual closed early, primarily due to a change in HCC standard of care systemic therapy. Statistics were amended to report data as of 7/1/2022, projecting 155 OS events providing 65% power for the original hypothesis, with the same alpha. OS and PFS were estimated by Kaplan-Meier and arms compared using log-rank test. Cox proportional hazards models were used to analyze treatment effect. TTP was estimated with cumulative incidence and arms compared using Gray's test. Secondary endpoints were tested with 2-sided alpha=0.05. <h3>Results</h3> Of 193 patients accrued from April 2013 to March 2021 from 23 sites, 177 eligible patients were randomized to S (n=92) vs. SBRT/S (n=85). Median age was 66 years (27-84); 41% had Hepatitis C and 19% had Hepatitis B or B/C. The majority were stage BCLC C (82%), with macrovascular invasion (74%). 4% had metastases. Median follow-up for all and alive patients was 13.2 and 33.7 months, respectively. With 153 OS events, median OS was improved from 12.3 months (90% CI 10.6, 14.3) with S to 15.8 months (90% CI 11.4-19.2) with SBRT/S (HR=0.77, 1-sided p=0.0554). After adjusting for PS, M stage, Child Pugh A5 vs. 6, and degree of vascular HCC, OS was statistically significantly improved for SBRT/S (HR=0.72, 95% CI 0.52-0.99, 2-sided Cox p=0.042). Median PFS was improved from 5.5 months (95% CI 3.4-6.3) with S to 9.2 months (95% CI 7.5-11.9) with SBRT/S (HR=0.55, 95% CI 0.40-0.75, 2-sided p=0.0001). TTP was also improved with SBRT/S (HR=0.69, 95% CI 0.48-0.998, 2-sided Gray's p=0.034). Treatment-related grade 3+ AEs were not significantly different (S - 42%, SBRT/S - 47%; p=0.52). There was one grade 5 treatment-related AE, in the S arm. <h3>Conclusion</h3> Adding SBRT improved OS, PFS, and TTP in patients with advanced HCC, compared to Sorafenib alone, with no significant increase in AEs." @default.
• W4308984611 created "2022-11-20" @default.
• W4308984611 creator A5001218876 @default.
• W4308984611 creator A5002869810 @default.
• W4308984611 creator A5012611477 @default.
• W4308984611 creator A5015996833 @default.
• W4308984611 creator A5016694714 @default.
• W4308984611 creator A5028300558 @default.
• W4308984611 creator A5030824378 @default.
• W4308984611 creator A5045903561 @default.
• W4308984611 creator A5046255995 @default.
• W4308984611 creator A5046828520 @default.
• W4308984611 creator A5053648453 @default.
• W4308984611 creator A5057372621 @default.
• W4308984611 creator A5065553522 @default.
• W4308984611 creator A5071975886 @default.
• W4308984611 creator A5076007484 @default.
• W4308984611 creator A5077084335 @default.
• W4308984611 creator A5081626404 @default.
• W4308984611 creator A5082122816 @default.
• W4308984611 creator A5084655772 @default.
• W4308984611 creator A5085943016 @default.
• W4308984611 date "2022-12-01" @default.
• W4308984611 modified "2023-10-11" @default.
• W4308984611 title "NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937)" @default.
• W4308984611 doi "https://doi.org/10.1016/j.ijrobp.2022.09.002" @default.
• W4308984611 hasPublicationYear "2022" @default.
• W4308984611 type Work @default.
• W4308984611 citedByCount "17" @default.
• W4308984611 countsByYear W43089846112023 @default.
• W4308984611 crossrefType "journal-article" @default.
• W4308984611 hasAuthorship W4308984611A5001218876 @default.
• W4308984611 hasAuthorship W4308984611A5002869810 @default.
• W4308984611 hasAuthorship W4308984611A5012611477 @default.
• W4308984611 hasAuthorship W4308984611A5015996833 @default.
• W4308984611 hasAuthorship W4308984611A5016694714 @default.
• W4308984611 hasAuthorship W4308984611A5028300558 @default.
• W4308984611 hasAuthorship W4308984611A5030824378 @default.
• W4308984611 hasAuthorship W4308984611A5045903561 @default.
• W4308984611 hasAuthorship W4308984611A5046255995 @default.
• W4308984611 hasAuthorship W4308984611A5046828520 @default.
• W4308984611 hasAuthorship W4308984611A5053648453 @default.
• W4308984611 hasAuthorship W4308984611A5057372621 @default.
• W4308984611 hasAuthorship W4308984611A5065553522 @default.
• W4308984611 hasAuthorship W4308984611A5071975886 @default.
• W4308984611 hasAuthorship W4308984611A5076007484 @default.
• W4308984611 hasAuthorship W4308984611A5077084335 @default.
• W4308984611 hasAuthorship W4308984611A5081626404 @default.
• W4308984611 hasAuthorship W4308984611A5082122816 @default.
• W4308984611 hasAuthorship W4308984611A5084655772 @default.
• W4308984611 hasAuthorship W4308984611A5085943016 @default.
• W4308984611 hasConcept C126322002 @default.
• W4308984611 hasConcept C143998085 @default.
• W4308984611 hasConcept C2778019345 @default.
• W4308984611 hasConcept C2778695046 @default.
• W4308984611 hasConcept C2989005 @default.
• W4308984611 hasConcept C509974204 @default.
• W4308984611 hasConcept C71924100 @default.
• W4308984611 hasConceptScore W4308984611C126322002 @default.
• W4308984611 hasConceptScore W4308984611C143998085 @default.
• W4308984611 hasConceptScore W4308984611C2778019345 @default.
• W4308984611 hasConceptScore W4308984611C2778695046 @default.
• W4308984611 hasConceptScore W4308984611C2989005 @default.
• W4308984611 hasConceptScore W4308984611C509974204 @default.
• W4308984611 hasConceptScore W4308984611C71924100 @default.
• W4308984611 hasIssue "5" @default.
• W4308984611 hasLocation W43089846111 @default.
• W4308984611 hasOpenAccess W4308984611 @default.
• W4308984611 hasPrimaryLocation W43089846111 @default.
• W4308984611 hasRelatedWork W2327375634 @default.
• W4308984611 hasRelatedWork W2330289123 @default.
• W4308984611 hasRelatedWork W2338561416 @default.
• W4308984611 hasRelatedWork W2809719602 @default.
• W4308984611 hasRelatedWork W3081388035 @default.
• W4308984611 hasRelatedWork W3151326415 @default.
• W4308984611 hasRelatedWork W3171402486 @default.
• W4308984611 hasRelatedWork W4214929818 @default.
• W4308984611 hasRelatedWork W4232617294 @default.
• W4308984611 hasRelatedWork W4323536446 @default.
• W4308984611 hasVolume "114" @default.
• W4308984611 isParatext "false" @default.
• W4308984611 isRetracted "false" @default.
• W4308984611 workType "article" @default.